Frontlight ResearchEarly access
Taking people in United StatesPhase 3
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Key facts
- Who runs it
- Amgen
- Where
- Doral, Los Angeles, Miami, and Pembroke Pines, United StatesSee the 4 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 159 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 26 Sept 2033
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Inebilizumab
- Tacrolimus
- Record updated
- 1 October 2026
Who can take part
- Age
- 18 years to 79 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Adults aged ≥18 years and <80 years
- Able and willing to provide written informed consent
- Primary membranous nephropathy (PMN) confirmed by renal biopsy (performed during screening or within 5 years before screening), or biopsy exemption for participants with anti-PLA2R antibody ≥20 RU/mL at screening
- Participants with diabetes Hemoglobin A1c (HbA1c) <7.5% require a renal biopsy report within 2 years before screening (or biopsy during screening) demonstrating PMN without diabetic nephropathy
- Urine protein-to-creatinine ratio (UPCR) ≥3.5 from a 24-hour urine collection at screening
- Receiving a maximally tolerated Angiotensin-Converting Enzyme (ACE) inhibitor or (Angiotensin II receptor blocker) ARB for ≥3 months before randomization with adequately controlled blood pressure (<140/90 mmHg)
Who cannot take part
- Recent treatment with prohibited therapies, including: B-cell-depleting biologics or other biologic immunomodulators, calcineurin inhibitors, alkylating agents within 3 months;( except history of resistance to calcineurin inhibitors); other immunosuppressive agents within 4 weeks; glucocorticoids within 1 month, or live or live-attenuated vaccines (within 4 weeks before randomization); Note: Other protocol-defined Inclusion/Exclusion criteria may apply
- Secondary membranous nephropathy (e.g., due to autoimmune disease, infection, malignancy, or medications)
- History of solid organ or cell transplantation or progressive multifocal leukoencephalopathy
- Estimated glomerular filtration rate (eGFR) <40 mL/min/1.73 m\^2 , ≥30% decline in eGFR during the previous 24 weeks, need for dialysis, kidney replacement therapy, kidney transplant, or planned transplant during the study
- Active HIV, hepatitis B infection, Hepatitis B surface antigen (HBsAg) positive, active hepatitis C infection, uncontrolled diabetes (HbA1c ≥7.5%), active or inadequately treated tuberculosis, recurrent herpes zoster or opportunistic infections, clinically significant active infection, recurrent serious infections, or immunodeficiency disorders
- Clinically significant laboratory abnormalities, including severe anemia, neutropenia, thrombocytopenia, low Cluster of Differentiation (CD19+) B-cell count, hepatic dysfunction, or immunoglobulin G (IgG) <400 mg/dL
- Recent thromboembolic event (within 3 months)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
This trial is currently available in United States.
- Bioresearch Partner-Jackson WestDoral, United StatesTaking people
- Academic Medical Research InstituteLos Angeles, United StatesTaking people
- Bioresearch Partner- Martin Luther King Jr.Miami, United StatesTaking people
- BioResearch Partner - Pembroke PinesPembroke Pines, United StatesTaking people
About the trial
What the trial wants to find out
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
The 2 groups in the trial
- InebilizumabTreatment being tested
Participants will receive inebilizumab via intravenous (IV) infusion
- TacrolimusExisting treatment, for comparison
Participants will receive tacrolimus orally.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3 Randomized, Open-Label Multicenter Study to Evaluate Efficacy and Safety of Inebilizumab in Adult Participants With Primary Membranous Nephropathy (PMN)
- Criteria questions
- Built from NCT07851220, who can take part
- Record updated
- 1 October 2026